Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Deletion of the diabetes candidate gene Slc16a13 in mice

ABSTRACT: The metabolome of plasma and liver lysates of Slc16a13 knockout mice was analyzed. Genome-wide association studies identified SLC16A13 as novel target gene in type 2 diabetes. The SLC16A13 gene encodes for SLC16A13/MCT13, a member of the solute carrier 16 family of monocarboxylate transporters. So far, biology and physiological function of SLC16A13 is unknown. Deletion of Slc16a13 is hypothezised to affect intrahepatocellular monocarboxylate availability, that drives increased oxidative phosphorylation, while reducing hepatic lipid content, thereby attenuating hepatic insulin resistance.

ORGANISM(S): Mouse Mus Musculus

TISSUE(S): Liver

DISEASE(S): Diabetes

SUBMITTER: Andreas Birkenfeld

PROVIDER: ST001643 | MetabolomicsWorkbench | Wed Jan 06 00:00:00 GMT 2021

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Similar Datasets

Mouse HFD Liver Skeletal Muscle SLC16A13 Knock-Out

Project description:Genome-wide association identified SLC16A13 as novel type 2 diabetes gene locus. The SLC16A13 gene encodes for SLC16A13/MCT13, member of the solute carrier 16 family of monocarboxylate transporters. This transporter family recently raised interest in metabolic research with the identification of SLC16A11 polymorphisms associated with type 2 diabetes; and human as well as mouse data suggest causal relationship between SLC16A11/MCT11 transporter dysfunction and type 2 diabetes development. In contrast, SLC16A13 biology and physiological function is not characterized at all. Here, we validate SLC16A13 as monocarboxylate transporter expressed at the plasma membrane and report the first Slc16a13 knockout mouse line. Deletion of Slc16a13 ameliorates metabolic disease in the context of diet-induced obesity. The improved metabolic phenotype is characterized by increased mitochondrial respiration in the liver, leading to reduced hepatic lipid accumulation and increased insulin sensitivity of Slc16a13 knockout mice. Mechanistically, we propose reduced intracellular lactate availability in Slc16a13 knockout hepatocytes, affecting hepatic energy metabolism by AMPK activation and increased oxidative phosphorylation, reducing hepatic lipid content and insulin resistance in obese mice. Together, these data suggest SLC16A13/MCT13 as potential novel target to treat fatty liver, insulin resistance and related metabolic disorders.

2021-06-24 | GSE152937 | GEO

Epistasis-driven identification of SLC25A51 as a regulator of human mitochondrial NAD import

Project description:About a thousand genes in the human genome encode for membrane transporters. Among these, several solute carrier proteins (SLCs), representing the largest group of transporters, are still orphan and lack functional characterization. We reasoned that assessing genetic interactions among SLCs may be an efficient way to obtain functional information allowing their deorphanization. Here we describe a network of strong genetic interactions indicating a contribution to mitochondrial respiration and redox metabolism for SLC25A51/MCART1, an uncharacterized member of the SLC25 family of transporters. Through a combination of metabolomics, genomics and genetics approaches, we demonstrate a role for SLC25A51 as enabler of mitochondrial import of NAD, showcasing the potential of genetic interaction-driven functional gene deorphanization.

2021-03-29 | MTBLS2205 | MetaboLights

Next Generation Sequencing Analysis of Mycfl/fl and MycΔIE, ERT2 intestinal transcriptomes

Project description:Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in developed countries, with extremely limited therapeutic options. MYC is a highly pleiotropic transcription factor with broad biological functions. However, the effect of intestinal MYC on metabolic diseases has not been studied. Here, an unexpected role for intestinal MYC in NAFLD was uncovered. MYC was increased in ileum biopsies from obese people and positively correlated with body-mass index. Intestine-specific reduction of MYC in mice improved high-fat diet (HFD) -induced obesity and hepatic steatosis. Mechanistically, reduced expression of MYC in the intestine promoted glucagon-like peptide-1 (GLP-1) production and secretion via upregulating carbohydrate-responsive element binding protein (ChREBP) and solute carrier family 2, member 2 (GLUT2)/solute carrier family 5, member 1 (SGLT1), respectively. Furthermore, 10058-F4, a MYC inhibitor, had therapeutic effects on HFD-induced metabolic disorders, accompanied by increased GLP-1 and reduced ceramides in the serum. This study highlights intestinal MYC as a putative drug target against NAFLD.

2021-05-10 | GSE155460 | GEO

Equilibrative Nucleoside Transporter 3 is an IFN-stimulated Gene that Facilitates Viral Genome Release

Project description:An increasing body of evidence emphasizes the role of metabolic reprogramming in immune cells to fight off infections. However, little is known about the regulation of metabolite transporters that facilitate and support metabolic demands. In this study, we found that the expression of Equilibrative Nucleoside Transporter 3 (ENT3, encoded by SoLute Carrier family 29 member 3, Slc29a3) is part of the innate immune response which is rapidly upregulated upon pathogen insults. The transcription of Slc29a3 is directly under the regulation of IFN-induced signaling, positioning this metabolite transporter as an Interferon-stimulated gene (ISG). Suprisingly, we unveil that several viruses, including SARS-CoV2, require ENT3 to facilitate their entry into the cytoplasm. The removal or suppression of ENT3 expression is sufficient to significantly decrease viral replication in vitro and in vivo. Our study reveals that ENT3 is a pro-viral ISG co-opted by some viruses for a survival advantage.

2022-11-08 | GSE216974 | GEO

Regulation of hypothalamic gene expression by glucocorticoid: implications for energy homeostasis

Project description:The current study has investigated the hypothalamic gene expressions regulated by glucocorticoid (GC), key hormones in energy homeostasis. Using serial analysis of gene expression (SAGE) method, we have studied the effects of adrenalectomy (ADX) and GC on the transcriptomes of mouse hypothalamus. Approximately, 180 000 SAGE tags, which correspond to 50 000 tag species, were isolated from each group of intact or adrenalectomized mice, as well as 1, 3 and 24 hours after GC injection. ADX has upregulated diazepam binding inhibitor gene expression, while downregulating vomeronasal 1 receptor D4, genes involved in mitochondrial phosphorylation (cytochrome c oxidase 1 and NADH dehydrogenase 3), 3b-hydroxysteroid dehydrogenase-1, and prostaglandin D2 synthase. GC has increased the gene expression levels of dehydrogenase/reductase member 3, prostaglandin D2 synthase, solute carrier family 4 member 4, and five cytoskeletal proteins including myosin light chain phosphorylatable fast and troponin C2 fast. On the other hand, GC has reduced the mRNA levels of calmodilin 1 and expressed sequence tag similar to (EST) calmodilin 2, ATP synthase F0 subunit 6, and solute carrier family 4 member 3. Moreover, seven uncharacterized and 43 novel transcripts were modulated by ADX and GC. The current study has identified genes that may regulate hypothalamic systems governing energy balance in response to ADX and GC. Keywords: Hormone effect analysis

2006-09-22 | GSE3366 | GEO

Transcriptome of Immortalized Mouse Corneal Endothelial Cells with SLC4A11 deficiency

Project description:Mutations in the solute-linked carrier family 4 member 11 (SLC4A11) gene are associated with several corneal endothelial dystrophies, in all of which visually significant cornea edema may require corneal transplantation. To elucidate the pathogenesis of SLC4A11 associated corneal endothelial dystrophies, we analyzed the transcriptome of immortalized mouse corneal endothelial cells (Slc4a11-/- MCEnC) and Slc4a11+/+ MCEnC as controls.

2020-08-13 | GSE142635 | GEO

ACP Acylation Is an Acetyl-CoADependent Modification Required for Electron Transport Chain Assembly

Project description:The electron transport chain (ETC) is an important participant in cellular energy conversion, but its biogenesis presents the cell with numerous challenges. To address these complexities, the cell utilizes ETC assembly factors, which include the LYR protein family. Each member of this family interacts with the mitochondrial acyl carrier protein (ACP), the scaffold protein upon which the mitochondrial fatty acid synthesis (mtFAS) pathway builds fatty acyl chains from acetyl-CoA. We demonstrate that the acylated form of ACP is an acetyl-CoA-dependent allosteric activator of the LYR protein family used to stimulate ETC biogenesis. By tuning ETC assembly to the abundance of acetyl-CoA, which is the major fuel of the TCA cycle and ETC, this system could provide an elegant mechanism for coordinating the assembly of ETC complexes with one another and with substrate availability.

2022-07-11 | PXD035000 | Pride

Transcriptome of Human Primary Corneal Endothelial Cells with SLC4A11 deficiency

Project description:Mutations in the solute-linked carrier family 4 member 11 (SLC4A11) gene are associated with several corneal endothelial dystrophies, in all of which visually significant cornea edema may require corneal transplantation. To elucidate the pathogenesis of SLC4A11 associated corneal endothelial dystrophies, we analyzed the transcriptome of SLC4A11 knock-down primary human corneal endothelium (SLC4A11 KD pHCEnC) and scrambled RNA treated pHCEnC as controls.

2020-08-13 | GSE142636 | GEO

RNA sequencing analysis of SLC6A15 overexpression in papillary thyroid cancer cells

Project description:Solute Carrier Family 6 Member 15 (SLC6A15) has been found with dysregulated expression in several kinds of cancers. However, its expression pattern and biological functions in papillary thyroid cancer (PTC) remain unknown. To explore the role of SLC6A15 in PTC, transcription profiling analysis was performed in KTC1 cells with or without SLC6A15 overexpression.

2020-09-21 | GSE157646 | GEO

The Slc25a47 locus is a novel determinant of hepatic mitochondrial function implicated in liver fibrosis

Project description:Background & Aims: Transporters of the SLC25 mitochondrial carrier superfamily bridge cytoplasmic and mitochondrial metabolism by channeling metabolites across mitochondrial membranes and are pivotal for metabolic homeostasis. Despite their physiological relevance as gatekeepers of cellular metabolism, most of the SLC25 family members remain uncharacterized. We undertook a comprehensive tissue distribution analysis of all Slc25 family members across metabolic organs and identified SLC25A47 as a liver-specific mitochondrial carrier. Method: We used a murine loss-of-function (LOF) model to unravel the role of this transporter in mitochondrial and hepatic homeostasis. We performed extensive metabolic phenotyping and molecular characterization of Slc25a47hep-/- mice. Results: Slc25a47hep-/- mice displayed a wide variety of metabolic abnormalities, as a result of sustained energy deficiency in the liver originating from impaired mitochondrial respiration in this organ. This mitochondrial phenotype was associated with a robust activation of the mitochondrial stress response in the liver, which in turn, induced the secretion of several mitokines, amongst which FGF21 played a preponderant role in the translation of the effects of the MSR on systemic physiology. To dissect the FGF21-dependent and -independent physiological changes induced by the loss of Slc25a47, we generated a double Slc25a47-Fgf21 LOF mouse model, and demonstrated that several aspects of the hypermetabolic state was entirely driven by hepatic secretion of FGF21. On the other hand, the metabolic fuel inflexibility induced by loss of Slc25a47 could not be rescued by genetical removal of Fgf21. Conclusion: Collectively, our data place SLC25A47 at the center of mitochondrial homeostasis, which upon dysfunction triggers robust liver-specific and systemic adaptive stress responses.

2022-06-21 | GSE195479 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data